<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS156677</article-id><article-id pub-id-type="doi">10.1101/2022.11.05.515268</article-id><article-id pub-id-type="archive">PPR567032</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><italic>In vivo</italic><sup>18</sup>F-DOPA PET imaging identifies a dopaminergic deficit in a rat model with a G51D α-synuclein mutation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Morley</surname><given-names>Victoria</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dolt</surname><given-names>Karamjit Singh</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Alcaide-Corral</surname><given-names>Carlos J.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Walton</surname><given-names>Tashfeen</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lucatelli</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mashimo</surname><given-names>Tomoji</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tavares</surname><given-names>Adriana A. S.</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Kunath</surname><given-names>Tilo</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Centre for Regenerative Medicine, Institute for Regeneration and Repair, School of Biological Sciences, The University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU, UK</aff><aff id="A2"><label>2</label>Division of Animal Genetics, Laboratory Animal Research Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639</aff><aff id="A3"><label>3</label>University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK</aff><author-notes><corresp id="CR1">
<label>*</label>Corresponding authors: <email>adriana.tavares@ed.ac.uk</email>, <email>tilo.kunath@ed.ac.uk</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>06</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="preprint"><day>05</day><month>11</month><year>2022</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Parkinson’s disease (PD) is a neurodegenerative condition with several major hallmarks, including loss of <italic>substantia nigra</italic> neurons, reduction in striatal dopaminergic function, and formation of α-synuclein-rich Lewy bodies. Mutations in <italic>SNCA</italic>, encoding for α-synuclein, are a known cause of familial PD, and the G51D mutation causes a particularly aggressive form of the condition. CRISPR/Cas9 technology was used to introduce the G51D mutation into the endogenous rat <italic>SNCA</italic> gene. <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats were born in Mendelian ratios and did not exhibit any severe behavourial defects. <italic>L</italic>-3,4-dihydroxy-6-<sup>18</sup>F-fluorophenylalanine (<sup>18</sup>F-DOPA) positron emission tomography (PET) imaging was used to investigate this novel rat model. Wild-type (WT), <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats were characterised over the course of ageing (5, 11, and 16 months old) using <sup>18</sup>F-DOPA PET imaging and kinetic modelling. We measured the influx rate constant (<italic>K<sub>i</sub></italic>) and effective distribution volume ratio (<italic>EDVR</italic>) of <sup>18</sup>F-DOPA in the striatum relative to the cerebellum in WT, <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats. A significant reduction in <italic>EDVR</italic> was observed in <italic>SNCA</italic><sup>G51D/G51D</sup> rats at 16 months of age indicative of increased dopamine turnover. Furthermore, we observed a significant asymmetry in EDVR between the left and right striatum in aged <italic>SNCA</italic><sup>G51D/G51D</sup> rats. The increased and asymmetric dopamine turnover observed in the striatum of aged <italic>SNCA</italic><sup>G51D/G51D</sup> rats is similar to prodromal PD, which suggests the presence of compensatory mechanisms. <italic>SNCA</italic><sup>G51D</sup> rats represent a novel genetic model of PD, and kinetic modelling of <sup>18</sup>F-DOPA PET data has identified a highly relevant early disease phenotype.</p></abstract><kwd-group><kwd>Parkinson’s</kwd><kwd>G51D α-synuclein mutation</kwd><kwd>rat model</kwd><kwd>PET imaging</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Parkinson’s disease (PD) is a common progressive neurodegenerative condition affecting ~1% of people over the age of 60 (<xref ref-type="bibr" rid="R38">Reeve et al., 2014)</xref>. The condition results in deficits of motor function including abnormal posture and gait, tremor and rigidity (<xref ref-type="bibr" rid="R15">Gelb et al., 1999</xref>; <xref ref-type="bibr" rid="R26">Lees et al., 2009</xref>). Characteristic neuropathological findings include the loss of neurons from the <italic>substantia nigra pars compacta</italic> (SNpc) which project axons to the striatum where dopamine (DA) is released (<xref ref-type="bibr" rid="R3">Bernheimer et al., 1973</xref>). The pathological hallmark of PD is the formation of Lewy bodies and Lewy neurites, complex intracellular inclusions abundant in α-synuclein protein (<xref ref-type="bibr" rid="R16">Gibb and Lees, 1988</xref>; <xref ref-type="bibr" rid="R45">Spillantini et al., 1997</xref>). Cases of familial PD have been shown to result from mutations in <italic>SNCA</italic>, encoding α-synuclein, and the G51D mutation (c.152 G&gt;A) has been identified to cause an early onset and aggressive form of PD with associated dementia and multiple system atrophy (<xref ref-type="bibr" rid="R22">Kiely et al., 2013</xref>; <xref ref-type="bibr" rid="R28">Lesage et al., 2013</xref>).</p><p id="P3">It has been extensively reported that PD patients have a decreased number of tyrosine hydroxylase (TH) positive neurons in the striatum when compared to controls, and this occurs when the condition has significantly progressed (<xref ref-type="bibr" rid="R20">Huot et al., 2007</xref>; <xref ref-type="bibr" rid="R23">Kordower et al., 2013</xref>). However, prior to significant neuronal loss, earlier deficits in presynaptic dopaminergic function in the striatum of PD patients can be investigated using positron emission tomography (PET) and the radiotracer <italic>L</italic>-3,4-dihydroxy-6-<sup>18</sup>F-fluorophenylalanine (<sup>18</sup>F-DOPA) (<xref ref-type="bibr" rid="R14">Garnett et al., 1983</xref>; <xref ref-type="bibr" rid="R34">Nahmias et al., 1985</xref>). <sup>18</sup>F-DOPA is metabolised in dopaminergic nerve terminals by the enzyme aromatic <italic>L</italic>-amino acid decarboxylase (AADC) to produce <sup>18</sup>F-DA, which is incorporated into synaptic vesicles and then released into the synaptic cleft following neuronal stimulation (<xref ref-type="bibr" rid="R13">Firnau et al., 1987</xref>). In patients with PD, dopaminergic function in the striatum is impaired, and the influx rate constant (<italic>K<sub>i</sub></italic>) of <sup>18</sup>F-DOPA is significantly decreased in the caudate and putamen (<xref ref-type="bibr" rid="R6">Brooks et al., 1990</xref>; <xref ref-type="bibr" rid="R19">Holthoff-Detto et al., 1997</xref>; <xref ref-type="bibr" rid="R40">Snow et al., 1993</xref>). Dopamine turnover can be measured with extended scanning time, and the effective distribution volume ratio (<italic>EDVR</italic>) of <sup>18</sup>F-DOPA can be calculated (<xref ref-type="bibr" rid="R41">Sossi et al., 2001</xref>). A decreased <italic>EDVR</italic> in the striatum indicates an increase in dopamine turnover, and this was observed in newly diagnosed PD patients relative to healthy controls prior to a decrease in <italic>K<sub>i</sub></italic> (<xref ref-type="bibr" rid="R43">Sossi et al., 2002</xref>). An increase in dopamine turnover was also observed in asymptomatic <italic>LRRK2</italic> mutation carriers before any evidence of changes in <italic>K<sub>i</sub></italic> (<xref ref-type="bibr" rid="R44">Sossi et al., 2010</xref>). This has been hypothesised to be a compensatory mechanism in early PD potentially due to upregulation of AADC decarboxylase activity (<xref ref-type="bibr" rid="R1">Adams et al., 2005</xref>; <xref ref-type="bibr" rid="R25">Lee et al., 2000</xref>). The rat is easily amenable to PET imaging and <italic>in vivo</italic> dopaminergic compensation has been reported in the 6-hydroxy-dopamine (6-OHDA) lesion rat model of PD (<xref ref-type="bibr" rid="R42">Sossi et al., 2009</xref>).</p><p id="P4">Genetic mouse and rat models of PD have been generated using different approaches with variable success. Although the majority of transgenic and knock-out/knock-in models are in the mouse, there have been several reported rat models. One transgenic rat model has been produced with a human <italic>SNCA</italic> construct with two PD mutations (A30P and A53T) under control of the rat <italic>TH</italic> promoter, and the major deficits reported in this model were olfactory (<xref ref-type="bibr" rid="R27">Lelan et al., 2011</xref>). A bacterial artificial chromosome (BAC) transgenic rat model expressing human <italic>SNCA</italic> with the E46K mutation identified a trend for decreased immunostaining for TH in the striatum and α-synuclein aggregates were identified in neuronal processes in the striatum (<xref ref-type="bibr" rid="R9">Cannon et al., 2013</xref>). The most representative genetic rat model of PD to date used a human BAC transgene to over-express WT human <italic>SNCA</italic> (<italic>BAC-hSNCA</italic>) (<xref ref-type="bibr" rid="R35">Nuber et al., 2013</xref>). Transgenic rats were observed to have significantly decreased expression of TH in the striatum as well as significantly decreased striatal dopamine levels in aged <italic>BAC-hSNCA</italic> rats compared with healthy controls (<xref ref-type="bibr" rid="R35">Nuber et al., 2013</xref>). Furthermore, neuritic α-synuclein pathology was identified in the striatum of aged transgenic rats (<xref ref-type="bibr" rid="R35">Nuber et al., 2013</xref>).</p><p id="P5">To date the majority of genetic rat models of PD have been generated by the random insertion of a transgene or the knock-out of a PD-related gene (<xref ref-type="bibr" rid="R10">Creed and Goldberg, 2018</xref>). Replicating the precise single amino acid substitution observed in PD kindreds has become possible in the rat with Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) genome engineering (<xref ref-type="bibr" rid="R48">Yoshimi et al., 2014</xref>). Here, we used CRISPR/Cas9 and a donor oligonucleotide in rat zygotes to mutate glycine-51 to aspartic acid (G51D) in rat <italic>SNCA</italic> exon 3 to produce a novel <italic>SNCA</italic><sup>G51D</sup> rat model of PD. Striatal dopamine metabolism and turnover were investigated in <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats over the course of ageing using <sup>18</sup>F-DOPA PET imaging and kinetic modelling.</p></sec><sec id="S2" sec-type="materials | methods"><title>Materials And Methods</title><sec id="S3"><title>Point mutation in rat genome with CRISPR/Cas9</title><p id="P6">CRISPR/Cas9 constructs used were the gRNA_Cloning vector (a gift from George Church, Addgene plasmid # 41824; <ext-link ext-link-type="uri" xlink:href="http://n2t.net/addgene:41824">http://n2t.net/addgene:41824</ext-link>; RRID:Addgene_41824) and humanised Cas9 nuclease vector (a gift from George Church, Addgene plasmid # 41815; <ext-link ext-link-type="uri" xlink:href="http://n2t.net/addgene:41815">http://n2t.net/addgene:41815</ext-link>; RRID:Addgene_41815) (<xref ref-type="bibr" rid="R30">Mali et al., 2013</xref>). The gRNA sequence was designed, synthesised inserted into the gRNA_Cloning vector into the <italic>Afl</italic>II site. The gRNA sequence is: 5’-GTCGTTCATGGAGTGACAAC-3’. The gRNA and Cas9 vectors were each linearized with <italic>XhoI</italic> and <italic>in vitro</italic> transcribed using a MessageMAXT7 ARCA-Capped Message Transcription Kit (CELLSCRIPT, Madison, WI, USA). A 80-nt ssDNA mutant donor oligonucleotide with the desired 2-bp mutation (G<bold>GA</bold> to G<bold>AT</bold>) was synthesised. The sequence of the ssDNA donor is: 5’-CAATTCTTTTTTTAGGTTCCAAAACTAAGGAGGGAGTCGTTCATGatGTGACAACAGGTA AGCTCTGTTGTCTTTTATCC-3’. The gRNA, <italic>Cas9</italic> mRNA, and ssDNA donor oligonucleotide were co-injected into male pronuclei of F344/Stm rat zygotes. Eleven (11) founder rats were screened by Sanger sequencing. Five (5) founders had mutations in exon 3 of <italic>SNCA</italic>, and one founder had the desired G<bold>GA</bold> to G<bold>AT</bold> (G51D) mutation (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S1</xref>). This founder was mated to produce F1 progeny, and the mutation transferred through the germ-line as determined by Sanger sequencing of genomic DNA extracted from ear notches (<xref ref-type="fig" rid="F1">Figure 1A</xref>). Since the mutation introduced a new <italic>Bsp</italic>HI restriction site (<xref ref-type="fig" rid="F1">Figure 1B</xref>), subsequent genotyping was performed by <italic>SNCA</italic> exon 3 PCR (forward primer 5’-TGGTGGCTGTTTGTCTTCTG-3’ and reverse primer 5’-TCCTCTGAAGACAATGGCTTTT-3’), a <italic>Bsp</italic>HI restriction enzyme digest, and agarose gel electrophoresis (<xref ref-type="fig" rid="F1">Figure 1C</xref>).</p></sec><sec id="S4"><title>Animal husbandry</title><p id="P7">The breeding and maintenance of wild-type (WT), <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats, and the <italic>in vivo</italic> experiments conducted were approved by the UK Home Office under project licence PC6C08D7D. WT, <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats were analysed over the course of ageing at 5, 11, and 16 months using <sup>18</sup>F-DOPA PET imaging (n=3/4 per genotype per age-group).</p></sec><sec id="S5"><title>PET imaging</title><p id="P8"><sup>18</sup>F-DOPA was produced using a multi-step nucleophilic fluorination pathway, and used the TRACERlab MX synthesiser and cassette with the nucleophilic precursor to <sup>18</sup>F-DOPA (ABX Advanced Biochemical Compounds, PEDP-0062-H), with the final product formulated in PBS (<xref ref-type="bibr" rid="R31">Martin et al., 2013</xref>).</p><p id="P9">Imaging was conducted under general anaesthesia and used Isoflurane in 0.6 L/min O<sub>2</sub> and 0.4 L/min N<sub>2</sub>O<sub>2</sub>. 10 mg/kg Carbidopa (Sigma-Aldrich, C1335), then 10 mg/kg Entacapone (Sigma-Aldrich, SML-0654) were injected intravenously to prevent the peripheral metabolism of <sup>18</sup>F-DOPA by AADC and catechol-O-methyltransferase (COMT), respectively (<xref ref-type="bibr" rid="R46">Walker et al., 2013a</xref>). Thirty minutes after injection of Carbidopa and Entacapone, 18.5 +/- 7.1 MBq (mean +/- SD) of <sup>18</sup>F-DOPA was injected as a bolus via the tail vein. Activity in the empty syringe was measured, with the activity injected calculated and decay corrected. Dynamic PET imaging lasted 2 hours.</p><p id="P10">Images were obtained using the nanoScan PET/CT scanner (Mediso Medical Imaging Systems, Budapest, Hungary), with PET/CT data acquired using Nucline™ v2.01 acquisition software. Prior to radiotracer injection a scout view CT image was acquired.</p><p id="P11">Dynamic PET imaging commenced upon injection of <sup>18</sup>F-DOPA and used a coincidence mode 1-5 and coincidence time window of 5ns. After PET imaging, CT data was acquired (trajectory semi-circular, maximum field of view, 480 projections, 55 kVp and 300 ms, binning 1:4) and used for attenuation correction of PET data.</p><p id="P12">The PET data that was reconstructed and extended from the olfactory bulbs to the caudal border of the heart. Reconstruction was 3D, dynamic and used the TeraTomo3D reconstruction method. Coincidence mode was 1-3, voxel size 0.4mm x 0.4mm x 0.4mm, used 4 iterations and 6 subsets, and was corrected for scatter, attenuation and randoms. Data was reconstructed into frames comprising 6 frames of 30 sec, 3 frames of 60 sec, 2 frames of 120 sec and 22 frames of 300 sec. All PET imaging data is freely accessible: <ext-link ext-link-type="uri" xlink:href="https://datashare.ed.ac.uk/handle/10283/4014">https://datashare.ed.ac.uk/handle/10283/4014</ext-link></p></sec><sec id="S6"><title>Image analysis</title><p id="P13">Images were analysed using PMOD 3.409 software (PMOD Technologies LLC) and a hand-drawn template. Volumes of interest (VOIs) comprised the left and right striatum, whole striatum, and the cerebellum which was a reference region for non-specific uptake. The same VOI template was used for all rats and were only moved into position over the respective anatomical areas. PET images for display purposes and to aid with VOI drawing were obtained by averaging over 0-120 minutes of emission data then a 1mm x 1mm x 1mm Gaussian filter was applied. Standardized uptake value (SUV) images were produced using rat body weight and the activity injected. Similarly, SUV TACs were calculated as follow SUV (g/ml) = activity concentration in the target VOI (kBq/ml)/(decay corrected amount of <sup>18</sup>F-DOPA injected (MBq)/weight of the rat (kg)).</p><p id="P14">Kinetic modelling used the Patlak reference tissue model and Logan reference tissue model to determine the <italic>K<sub>i</sub></italic> of <sup>18</sup>F-DOPA in the striatum and the distribution volume ratio (<italic>DVR</italic>) of <sup>18</sup>F-DOPA in the striatum relative to the cerebellum, respectively (<xref ref-type="bibr" rid="R29">Logan, 2000</xref>). The Patlak reference tissue model used 60 min of data and a <italic>t</italic>* of 10 min in accordance with previous studies in Sprague Dawley rats (<xref ref-type="bibr" rid="R24">Kyono et al., 2011</xref>). In contrast, the Logan reference tissue model used 120 min of data and <italic>t</italic>* of 30 min, which were parameters optimised from WT F344 rat data and these differ from other methods used to analyse PET data from Sprague Dawley rats (<xref ref-type="bibr" rid="R46">Walker et al., 2013a</xref>). The Logan reference tissue model was also used to determine the effective <italic>DVR (EDVR</italic>) of <sup>18</sup>F-DOPA which involved subtracting the TAC (kBq/ml) for the cerebellum from the TACs for the striatum before analysis (<xref ref-type="bibr" rid="R46">Walker et al., 2013a</xref>) and used 120 min of data and <italic>t</italic>* of 30 min. <italic>EDVR</italic> can be used to estimate the effective dopamine turnover (<xref ref-type="bibr" rid="R43">Sossi et al., 2002</xref>). Differences in <italic>EDVR</italic> between left and right striatum were also investigated by calculating asymmetry in <italic>EDVR</italic> which = (<italic>EDVR</italic> contralateral - <italic>EDVR</italic> ipsilateral)/<italic>EDVR</italic> contralateral (<xref ref-type="bibr" rid="R47">Walker et al., 2013b</xref>).</p></sec><sec id="S7"><title>Statistical analysis</title><p id="P15"><sup>18</sup>F-DOPA PET data from WT, <italic>SNCA</italic><sup>G51D/+</sup>, and <italic>SNCA</italic><sup>G51D/G51D</sup> rats are presented where appropriate as the mean +/- SEM. Results from age-matched WT, <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats were analysed using a 1-way ANOVA with Tukey’s multiple comparison test.</p></sec><sec id="S8" sec-type="results"><title>Results</title><sec id="S9"><title>Generation of the SNCA<sup>G51D</sup> rat model</title><p id="P16">The G51D mutation in PD patients is due to a single nucleotide change (c.152 G&gt;A) that mutates the Gly-51 codon (G<bold>G</bold>T) to G<bold>A</bold>T, encoding for aspartic acid. The rat <italic>SNCA</italic> Gly-51 codon is G<bold>GA</bold>, which requires a 2-nucleotide mutation to produce the Asp-51 codon G<bold>AT</bold>. <italic>Cas9</italic> mRNA, gRNA and ssDNA donor oligonucleotide with GAT codon were co-injected into F344/Stm rat zygotes. Eleven founder rats were screened by Sanger sequencing and 5 F0 rats had mutations in <italic>SNCA</italic>, but only one founder had the desired GGA to GAT (G51D) mutation in exon 3 of <italic>SNCA</italic> (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S1</xref>). This F0 founder rat was bred, and F1 animals with the G51D mutation were identified by Sanger sequencing confirming the mutation could transmit through the germ-line (<xref ref-type="fig" rid="F1">Figure 1A</xref>). All subsequent progeny from the sequence-confirmed F1 rats were PCR-genotyped taking advantage of a new <italic>Bsp</italic>HI restriction site introduced by the G51D mutation (<xref ref-type="fig" rid="F1">Figure 1B,C</xref>). Heterozygous <italic>SNCA</italic><sup>G51D/+</sup> matings produced progeny in Mendelian ratios suggesting the mutation did not reduce embryonic or fetal viability (<xref ref-type="fig" rid="F1">Figure 1D</xref>).</p></sec><sec id="S10"><title>Optimisation of <sup>18</sup>F-DOPA PET imaging in Fischer 344 rats</title><p id="P17">The methods used for the reconstruction of <italic>in vivo</italic> PET imaging experiments were optimised since the rat striatum is a small structure and the optimal acquisition and reconstruction of PET data is scanner dependent. A homogenous solution of <sup>18</sup>F-FDG was used in a National Electrical Manufacturers Association (NEMA) NU-4 mouse image quality (IQ) phantom (<xref ref-type="bibr" rid="R17">Harteveld et al., 2011</xref>). Imaging data was acquired and reconstructed using variations of several parameters (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2</xref>). The most promising reconstruction scenario used iterative methods and employed 4 iterations and 6 subsets (4i6S) at a normal resolution and a coincidence mode of 1-3. The <italic>in vivo</italic> imaging and kinetic modelling methods were optimised using data obtained from preliminary experiments using two WT F344 rats (<xref ref-type="fig" rid="F2">Figure 2</xref>). Time activity curves (TACs) and standardized uptake values (SUV) were calculated and plotted for striatum and cerebellum (<xref ref-type="fig" rid="F2">Figure 2B,C</xref>). The cerebellum was used as a reference region since it lacks AADC expression (<xref ref-type="bibr" rid="R2">Baker et al., 1991</xref>). Plotting the SUV ratio (SUVr) of the striatum and cerebellum for both rats showed the data was consistent and that the activity reached a pseudo-equilibrium between 50 min and 85 min (<xref ref-type="fig" rid="F2">Figure 2D</xref>). This data indicated that methods used for kinetic modelling in recent PET imaging studies of models of PD were optimal (<xref ref-type="bibr" rid="R24">Kyono et al., 2011</xref>). Kinetic modeling using Patlak and Logan graphical analysis used data collected over 60 min and 180 min, respectively (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p></sec><sec id="S11"><title><sup>18</sup>F-DOPA PET imaging reveals a deficit in dopamine turnover</title><p id="P18">WT, <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats were subjected to <sup>18</sup>F-DOPA PET at 5, 11, and 16 months of age using the conditions optimised above. Data was analysed to determine SUV TACs from WT, <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats (<xref ref-type="fig" rid="F4">Figures 4A</xref>), and plotted to show the specific uptake of <sup>18</sup>F-DOPA into the striatum compared with the cerebellum.</p><p id="P19">The mean <italic>K<sub>i</sub></italic> values of <sup>18</sup>F-DOPA in 5-16 month old <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats compared with age-matched WT rats were not significantly different (<xref ref-type="fig" rid="F4">Figure 4B</xref>). The mean <italic>DVR</italic> and <italic>EDVR</italic> of <sup>18</sup>F-DOPA in the striatum relative to the cerebellum was significantly decreased in 16 month old rats compared to WT rats, but these differences were not observed at 5 and 11 months of age (<xref ref-type="fig" rid="F4">Figure 4C,D</xref>). The <italic>EDVR</italic> of <sup>18</sup>F-DOPA is the ratio of the distribution volumes of <sup>18</sup>F-DOPA in the specific and precursor compartments reduced by the factor <italic>k<sub>2</sub></italic>/(<italic>k<sub>2</sub> + k<sub>3</sub></italic>), and since <italic>EDVR</italic> is estimated to be the inverse of effective dopamine turnover (<xref ref-type="bibr" rid="R43">Sossi et al., 2002</xref>), the results indicate an increase in mean dopamine turnover in 16 month <italic>SNCA</italic><sup>G51D/G51D</sup> rats compared with age-matched WT rats. Interestingly, the mean asymmetry in the <italic>EDVR</italic> of <sup>18</sup>F-DOPA in the left and right striatum of 16 month old <italic>SNCA</italic><sup>G51D/G51D</sup> and <italic>SNCA</italic><sup>G51D/+</sup> rats were significantly different than age-matched WT rats (<xref ref-type="fig" rid="F4">Figure 4E</xref>). The <italic>EDVR</italic> asymmetry in <italic>SNCA</italic><sup>G51D/G51D</sup> rats was between -0.4 and 0.3, while the normal range determined for Sprague Dawley rats is between -0.1 and 1.0 (<xref ref-type="bibr" rid="R47">Walker et al., 2013b</xref>).</p></sec></sec></sec><sec id="S12" sec-type="discussion"><title>Discussion</title><p id="P20">The aim of the study was to characterise a novel <italic>SNCA</italic><sup>G51D</sup> rat model of Parkinson’s disease using <sup>18</sup>F-DOPA PET imaging. Experiments were conducted over an ageing time-course, since phenotypes were anticipated to worsen with time. In patients with PD, striatal dopaminergic function decreases prior to degeneration of nerve terminals (<xref ref-type="bibr" rid="R32">Morrish et al., 1998</xref>; <xref ref-type="bibr" rid="R33">1995</xref>; <xref ref-type="bibr" rid="R36">Nurmi et al., 2001</xref>).</p><p id="P21"><sup>18</sup>F-DOPA PET imaging data indicated no significant differences in mean <italic>K<sub>i</sub></italic> of <sup>18</sup>F-DOPA in the striatum of ageing <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats compared with age-matched WT rats (<xref ref-type="fig" rid="F4">Figure 4B</xref>). However, there was a significant decreased mean <italic>DVR</italic> and <italic>EDVR</italic> of <sup>18</sup>F-DOPA in the striatum of 16 month old <italic>SNCA</italic><sup>G51D/G51D</sup> rats compared with age-matched WT rats (<xref ref-type="fig" rid="F4">Figure 4C,D</xref>), which indicates increased dopamine turnover in the aged <italic>SNCA</italic><sup>G51D/G51D</sup> rats.</p><p id="P22">In early PD the <italic>EDVR</italic> of <sup>18</sup>F-DOPA in the striatum relative to the cerebellum is significantly decreased compared with healthy controls, which indicates increased effective dopamine turnover and this is likely due to a compensatory change in response to striatal dysfunction (<xref ref-type="bibr" rid="R43">Sossi et al., 2002</xref>). This data is supported by results from <sup>18</sup>F-DOPA PET imaging studies of asymptomatic MPTP lesioned monkeys which have also implicated increased effective dopamine turnover as a compensatory mechanism (<xref ref-type="bibr" rid="R11">Doudet et al., 1998</xref>). The significantly decreased mean <italic>EDVR</italic> in 16 month old <italic>SNCA</italic><sup>G51D/G51D</sup> rats may indicate a compensatory change in dopaminergic function in the striatum of <italic>SNCA</italic><sup>G51D/G51D</sup> rats following putative striatal dysregulation.</p><p id="P23">In PD the <italic>K<sub>i</sub></italic> of <sup>18</sup>F-DOPA in the striatum is significantly decreased compared with healthy controls (<xref ref-type="bibr" rid="R6">Brooks et al., 1990</xref>; <xref ref-type="bibr" rid="R7">Burn et al., 1994</xref>; <xref ref-type="bibr" rid="R19">Holthoff-Detto et al., 1997</xref>; <xref ref-type="bibr" rid="R39">Rinne et al., 2000</xref>), with <italic>K<sub>i</sub></italic> in the putamen reaching 57-80% of normal levels before symptoms of PD develop (<xref ref-type="bibr" rid="R32">Morrish et al., 1995</xref>; <xref ref-type="bibr" rid="R33">1998</xref>; <xref ref-type="bibr" rid="R36">Nurmi et al., 2001</xref>). The lack of change in mean <italic>K<sub>i</sub></italic> in the striatum of <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats suggests any potential phenotypes are being sufficiently compensated for in this model and reflects what is observed in patients with prodromal PD. In chemical lesion models of PD, TH has been found to be significantly increased in the striatum post lesioning, a compensatory mechanism in response to nerve damage, which either results in increased TH protein expression or involves morphological changes such as the expansion of nerve terminals (<xref ref-type="bibr" rid="R4">Bezard and Gross, 1998</xref>; <xref ref-type="bibr" rid="R5">Blanchard et al., 1995</xref>). Compensatory changes in dopaminergic terminals have also been shown to involve the upregulation of AADC activity and the downregulation of DATs (<xref ref-type="bibr" rid="R1">Adams et al., 2005</xref>; <xref ref-type="bibr" rid="R25">Lee et al., 2000</xref>). In 6-OHDA lesion models of PD, PET imaging studies have identified a complex relationship between the <italic>k<sub>ref</sub></italic> of <sup>18</sup>F-DOPA and the binding potential of <sup>11</sup>C-DTBZ (denervation severity) (<xref ref-type="bibr" rid="R46">Walker et al., 2013a</xref>).</p><p id="P24">Results measuring asymmetry in the <italic>EDVR</italic> of <sup>18</sup>F-DOPA showed decreased mean <italic>EDVR</italic> in the left striatum when compared to the right in 5 out of 6 groups of rats, with greatest asymmetry in 16 month old <italic>SNCA</italic><sup>G51D/G51D</sup> rats (<xref ref-type="fig" rid="F4">Figure 4E</xref>). Reasons that may explain the predilection for the left side could be due to the unique anatomy of the blood vessel supply to the brain in F344 rats which may result in non-uniform perfusion in this strain of rat (<xref ref-type="bibr" rid="R21">Iwasaki et al., 1995</xref>).</p><p id="P25"><italic>SNCA</italic><sup>G51D</sup> rats were generated using CRISPR/Cas9 technology to model the G51D α-synuclein mutation in humans. The G51D model has good construct validity, and mutant α-synuclein is expressed from the endogenous rat locus. <italic>SNCA</italic><sup>G51D</sup> rats have the potential to model the widespread neurological abnormalities found in PD and may be a more representative model of PD than the focal 6-OHDA lesion model, which has previously been studied using <sup>18</sup>F-DOPA PET imaging (<xref ref-type="bibr" rid="R24">Kyono et al., 2011</xref>; <xref ref-type="bibr" rid="R46">Walker et al., 2013a</xref>). Since rodent models of human disease are almost always less severe, we expected the <italic>SNCA</italic><sup>G51D</sup> rats to have phenotypes similar to early stages of the disease (<xref ref-type="bibr" rid="R37">Petrucci et al., 2016</xref>). <italic>SNCA</italic><sup>G51D</sup> may exhibit a subtle phenotype in rats due to protective factors such as β-synuclein which have been shown to the ameliorate PD-like phenotypes in mice (<xref ref-type="bibr" rid="R12">Fan et al., 2006</xref>; <xref ref-type="bibr" rid="R18">Hashimoto et al., 2001</xref>). Furthermore, rodents may lack key triggers or cellular components necessary for exhibiting a full PD phenotype. Differences in the <italic>SNCA</italic> sequence between rodents and humans may explain some of the difficulties in modelling genetic PD, since rodents, indeed most vertebrates, encode a threonine at position 53 which is a cause of PD in humans, and human A53T mice have demonstrated exaggerated motor deficits and α-synuclein pathology following removal of endogenous mouse α-synuclein (<xref ref-type="bibr" rid="R8">Cabin et al., 2005</xref>).</p></sec><sec id="S13" sec-type="conclusions"><title>Conclusion</title><p id="P26"><italic>SNCA</italic><sup>G51D/G51D</sup> rats show a significant increase in dopamine turnover in the striatum at 16 months of age, but not a significant decrease in Ki – dopamine synthesis and storage. These findings mimic the early stages of Parkinson’s, and may reflect the compensatory changes in the dopaminergic system observed in humans. <italic>SNCA</italic><sup>G51D</sup> rats represent an interesting model of early PD pathophysiology, and provide a tractable platform for investigating additional genetic or environmental triggers of Parkinson’s.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Information</label><media xlink:href="EMS156677-supplement-Supplementary_Information.docx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document" id="d153aAdEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S14"><title>Acknowledgements</title><p>This work was funded by a Carnegie Trust PhD Scholarship to VM, Parkinson’s UK Senior Fellowship to TK, a Wellcome Trust ISSF award to TK and AT. We thank Ms Yayoi Kunihiro for assistance in generation of the <italic>SNCA</italic><sup>G51D</sup> rat model.</p></ack><fn-group><fn id="FN1" fn-type="conflict"><p id="P27"><bold>Competing interests</bold></p><p id="P28">The authors declare no competing interests.</p></fn><fn id="FN2" fn-type="con"><p id="P29"><bold>Authors’ contribution</bold></p><p id="P30">VM, AT, and TK devised the study. The <italic>SNCA</italic><sup>G51D</sup> rat model was generated by TM (Kyoto University). KSD (University of Edinburgh) established genotyping of <italic>SNCA</italic><sup>G51D</sup> rats, maintained the rat colony, and conducted preliminary studies. The <sup>18</sup>F-DOPA radiotracer was synthesised by TW and CL (University of Edinburgh), and CCA (University of Edinburgh) provided assistance during <italic>in vivo</italic><sup>18</sup>F- DOPA PET imaging experiments. VM and AT designed and conducted PET experiments and data analysis. VM and TK wrote the manuscript and it was edited by AT.</p></fn></fn-group><ref-list><ref id="R1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JR</given-names></name><name><surname>van Netten</surname><given-names>H</given-names></name><name><surname>Schulzer</surname><given-names>M</given-names></name><name><surname>Mak</surname><given-names>E</given-names></name><name><surname>McKenzie</surname><given-names>J</given-names></name><name><surname>Strongosky</surname><given-names>A</given-names></name><name><surname>Sossi</surname><given-names>V</given-names></name><name><surname>Ruth</surname><given-names>TJ</given-names></name><name><surname>Lee</surname><given-names>CS</given-names></name><name><surname>Farrer</surname><given-names>M</given-names></name><etal/></person-group><article-title>PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation</article-title><source>Brain</source><year>2005</year><volume>128</volume><fpage>2777</fpage><lpage>2785</lpage></element-citation></ref><ref id="R2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>H</given-names></name><name><surname>Abate</surname><given-names>C</given-names></name><name><surname>Szabo</surname><given-names>A</given-names></name><name><surname>Joh</surname><given-names>TH</given-names></name></person-group><article-title>Species-specific distribution of aromatic L-amino acid decarboxylase in the rodent adrenal gland, cerebellum, and olfactory bulb</article-title><source>J Comp Neurol</source><year>1991</year><volume>305</volume><fpage>119</fpage><lpage>129</lpage></element-citation></ref><ref id="R3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernheimer</surname><given-names>H</given-names></name><name><surname>Birkmayer</surname><given-names>W</given-names></name><name><surname>Hornykiewicz</surname><given-names>O</given-names></name><name><surname>Jellinger</surname><given-names>K</given-names></name><name><surname>Seitelberger</surname><given-names>F</given-names></name></person-group><article-title>Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations</article-title><source>J Neurol Sci</source><year>1973</year><volume>20</volume><fpage>415</fpage><lpage>455</lpage></element-citation></ref><ref id="R4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bezard</surname><given-names>E</given-names></name><name><surname>Gross</surname><given-names>CE</given-names></name></person-group><article-title>Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach</article-title><source>Prog Neurobiol</source><year>1998</year><volume>55</volume><fpage>93</fpage><lpage>116</lpage></element-citation></ref><ref id="R5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanchard</surname><given-names>V</given-names></name><name><surname>Chritin</surname><given-names>M</given-names></name><name><surname>Vyas</surname><given-names>S</given-names></name><name><surname>Savasta</surname><given-names>M</given-names></name><name><surname>Feuerstein</surname><given-names>C</given-names></name><name><surname>Agid</surname><given-names>Y</given-names></name><name><surname>Javoy-Agid</surname><given-names>F</given-names></name><name><surname>Raisman-Vozari</surname><given-names>R</given-names></name></person-group><article-title>Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain</article-title><source>J Neurochem</source><year>1995</year><volume>64</volume><fpage>1669</fpage><lpage>1679</lpage></element-citation></ref><ref id="R6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Ibanez</surname><given-names>V</given-names></name><name><surname>Sawle</surname><given-names>GV</given-names></name><name><surname>Quinn</surname><given-names>N</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Mathias</surname><given-names>CJ</given-names></name><name><surname>Bannister</surname><given-names>R</given-names></name><name><surname>Marsden</surname><given-names>CD</given-names></name><name><surname>Frackowiak</surname><given-names>RS</given-names></name></person-group><article-title>Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy</article-title><source>Ann Neurol</source><year>1990</year><volume>28</volume><fpage>547</fpage><lpage>555</lpage></element-citation></ref><ref id="R7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burn</surname><given-names>DJ</given-names></name><name><surname>Sawle</surname><given-names>GV</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name></person-group><article-title>Differential diagnosis of Parkinson’s disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data</article-title><source>J Neurol Neurosurg Psychiatr</source><year>1994</year><volume>57</volume><fpage>278</fpage><lpage>284</lpage></element-citation></ref><ref id="R8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabin</surname><given-names>DE</given-names></name><name><surname>Gispert-Sanchez</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>D</given-names></name><name><surname>Auburger</surname><given-names>G</given-names></name><name><surname>Myers</surname><given-names>RR</given-names></name><name><surname>Nussbaum</surname><given-names>RL</given-names></name></person-group><article-title>Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background</article-title><source>Neurobiol Aging</source><year>2005</year><volume>26</volume><fpage>25</fpage><lpage>35</lpage></element-citation></ref><ref id="R9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannon</surname><given-names>JR</given-names></name><name><surname>Geghman</surname><given-names>KD</given-names></name><name><surname>Tapias</surname><given-names>V</given-names></name><name><surname>Sew</surname><given-names>T</given-names></name><name><surname>Dail</surname><given-names>MK</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Greenamyre</surname><given-names>JT</given-names></name></person-group><article-title>Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson’s disease features and enhances vulnerability to mitochondrial impairment</article-title><source>Exp Neurol</source><year>2013</year><volume>240</volume><fpage>44</fpage><lpage>56</lpage></element-citation></ref><ref id="R10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creed</surname><given-names>RB</given-names></name><name><surname>Goldberg</surname><given-names>MS</given-names></name></person-group><article-title>New Developments in Genetic rat models of Parkinson’s Disease</article-title><source>Mov Disord</source><year>2018</year><volume>33</volume><fpage>717</fpage><lpage>729</lpage></element-citation></ref><ref id="R11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doudet</surname><given-names>DJ</given-names></name><name><surname>Chan</surname><given-names>GL</given-names></name><name><surname>Holden</surname><given-names>JE</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name><name><surname>Aigner</surname><given-names>TA</given-names></name><name><surname>Wyatt</surname><given-names>RJ</given-names></name><name><surname>Ruth</surname><given-names>TJ</given-names></name></person-group><article-title>6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys</article-title><source>Synapse</source><year>1998</year><volume>29</volume><fpage>225</fpage><lpage>232</lpage></element-citation></ref><ref id="R12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Limprasert</surname><given-names>P</given-names></name><name><surname>Murray</surname><given-names>IVJ</given-names></name><name><surname>Smith</surname><given-names>AC</given-names></name><name><surname>Lee</surname><given-names>VMY</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Sopher</surname><given-names>BL</given-names></name><name><surname>La Spada</surname><given-names>AR</given-names></name></person-group><article-title>β-synuclein modulates α-synuclein neurotoxicity by reducing α-synuclein protein expression</article-title><source>Hum Mol Genet</source><year>2006</year><volume>15</volume><fpage>3002</fpage><lpage>3011</lpage></element-citation></ref><ref id="R13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firnau</surname><given-names>G</given-names></name><name><surname>Sood</surname><given-names>S</given-names></name><name><surname>Chirakal</surname><given-names>R</given-names></name><name><surname>Nahmias</surname><given-names>C</given-names></name><name><surname>Garnett</surname><given-names>ES</given-names></name></person-group><article-title>Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate</article-title><source>J Neurochem</source><year>1987</year><volume>48</volume><fpage>1077</fpage><lpage>1082</lpage></element-citation></ref><ref id="R14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garnett</surname><given-names>ES</given-names></name><name><surname>Firnau</surname><given-names>G</given-names></name><name><surname>Nahmias</surname><given-names>C</given-names></name></person-group><article-title>Dopamine visualized in the basal ganglia of living man</article-title><source>Nature</source><year>1983</year><volume>305</volume><fpage>137</fpage><lpage>138</lpage></element-citation></ref><ref id="R15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelb</surname><given-names>DJ</given-names></name><name><surname>Oliver</surname><given-names>E</given-names></name><name><surname>Gilman</surname><given-names>S</given-names></name></person-group><article-title>Diagnostic criteria for Parkinson disease</article-title><source>Arch Neurol</source><year>1999</year><volume>56</volume><fpage>33</fpage><lpage>39</lpage></element-citation></ref><ref id="R16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibb</surname><given-names>WR</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group><article-title>The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease</article-title><source>J Neurol Neurosurg Psychiatr</source><year>1988</year><volume>51</volume><fpage>745</fpage><lpage>752</lpage></element-citation></ref><ref id="R17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harteveld</surname><given-names>AA</given-names></name><name><surname>Meeuwis</surname><given-names>APW</given-names></name><name><surname>Disselhorst</surname><given-names>JA</given-names></name><name><surname>Slump</surname><given-names>CH</given-names></name><name><surname>Oyen</surname><given-names>WJG</given-names></name><name><surname>Boerman</surname><given-names>OC</given-names></name><name><surname>Visser</surname><given-names>EP</given-names></name></person-group><article-title>Using the NEMA NU 4 PET image quality phantom in multipinhole small-animal SPECT</article-title><source>J Nucl Med</source><year>2011</year><volume>52</volume><fpage>1646</fpage><lpage>1653</lpage></element-citation></ref><ref id="R18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Rockenstein</surname><given-names>E</given-names></name><name><surname>Mante</surname><given-names>M</given-names></name><name><surname>Mallory</surname><given-names>M</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name></person-group><article-title>β-Synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor</article-title><source>Neuron</source><year>2001</year><volume>32</volume><fpage>213</fpage><lpage>223</lpage></element-citation></ref><ref id="R19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holthoff-Detto</surname><given-names>VA</given-names></name><name><surname>Kessler</surname><given-names>J</given-names></name><name><surname>Herholz</surname><given-names>K</given-names></name><name><surname>Bönner</surname><given-names>H</given-names></name><name><surname>Pietrzyk</surname><given-names>U</given-names></name><name><surname>Würker</surname><given-names>M</given-names></name><name><surname>Ghaemi</surname><given-names>M</given-names></name><name><surname>Wienhard</surname><given-names>K</given-names></name><name><surname>Wagner</surname><given-names>R</given-names></name><name><surname>Heiss</surname><given-names>WD</given-names></name></person-group><article-title>Functional effects of striatal dysfunction in Parkinson disease</article-title><source>Arch Neurol</source><year>1997</year><volume>54</volume><fpage>145</fpage><lpage>150</lpage></element-citation></ref><ref id="R20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huot</surname><given-names>P</given-names></name><name><surname>Lévesque</surname><given-names>M</given-names></name><name><surname>Parent</surname><given-names>A</given-names></name></person-group><article-title>The fate of striatal dopaminergic neurons in Parkinson”s disease and Huntington”s chorea</article-title><source>Brain</source><year>2007</year><volume>130</volume><fpage>222</fpage><lpage>232</lpage></element-citation></ref><ref id="R21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>H</given-names></name><name><surname>Ohmachi</surname><given-names>Y</given-names></name><name><surname>Kume</surname><given-names>E</given-names></name><name><surname>Krieglstein</surname><given-names>J</given-names></name></person-group><article-title>Strain differences in vulnerability of hippocampal neurons to transient cerebral ischaemia in the rat</article-title><source>Int J Exp Pathol</source><year>1995</year><volume>76</volume><fpage>171</fpage><lpage>178</lpage></element-citation></ref><ref id="R22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiely</surname><given-names>AP</given-names></name><name><surname>Asi</surname><given-names>YT</given-names></name><name><surname>Kara</surname><given-names>E</given-names></name><name><surname>Limousin</surname><given-names>P</given-names></name><name><surname>Ling</surname><given-names>H</given-names></name><name><surname>Lewis</surname><given-names>P</given-names></name><name><surname>Proukakis</surname><given-names>C</given-names></name><name><surname>Quinn</surname><given-names>N</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><etal/></person-group><article-title>α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy?</article-title><source>Acta Neuropathol</source><year>2013</year><volume>125</volume><fpage>753</fpage><lpage>769</lpage></element-citation></ref><ref id="R23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kordower</surname><given-names>JH</given-names></name><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Dodiya</surname><given-names>HB</given-names></name><name><surname>Chu</surname><given-names>Y</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Adler</surname><given-names>CH</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Bartus</surname><given-names>RT</given-names></name></person-group><article-title>Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease</article-title><source>Brain</source><year>2013</year><volume>136</volume><fpage>2419</fpage><lpage>2431</lpage></element-citation></ref><ref id="R24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyono</surname><given-names>K</given-names></name><name><surname>Takashima</surname><given-names>T</given-names></name><name><surname>Katayama</surname><given-names>Y</given-names></name><name><surname>Kawasaki</surname><given-names>T</given-names></name><name><surname>Zochi</surname><given-names>R</given-names></name><name><surname>Gouda</surname><given-names>M</given-names></name><name><surname>Kuwahara</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Wada</surname><given-names>Y</given-names></name><name><surname>Onoe</surname><given-names>H</given-names></name><etal/></person-group><article-title>Use of [18F]FDOPA-PET for in vivo evaluation of dopaminergic dysfunction in unilaterally 6-OHDA-lesioned rats</article-title><source>EJNMMI Res</source><year>2011</year><volume>1</volume><elocation-id>25</elocation-id></element-citation></ref><ref id="R25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CS</given-names></name><name><surname>Samii</surname><given-names>A</given-names></name><name><surname>Sossi</surname><given-names>V</given-names></name><name><surname>Ruth</surname><given-names>TJ</given-names></name><name><surname>Schulzer</surname><given-names>M</given-names></name><name><surname>Holden</surname><given-names>JE</given-names></name><name><surname>Wudel</surname><given-names>J</given-names></name><name><surname>Pal</surname><given-names>PK</given-names></name><name><surname>de la Fuente-Fernandez</surname><given-names>R</given-names></name><name><surname>Calne</surname><given-names>DB</given-names></name><etal/></person-group><article-title>In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease</article-title><source>Ann Neurol</source><year>2000</year><volume>47</volume><fpage>493</fpage><lpage>503</lpage></element-citation></ref><ref id="R26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name></person-group><article-title>Parkinson’s disease</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>2055</fpage><lpage>2066</lpage></element-citation></ref><ref id="R27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lelan</surname><given-names>F</given-names></name><name><surname>Boyer</surname><given-names>C</given-names></name><name><surname>Thinard</surname><given-names>R</given-names></name><name><surname>Remy</surname><given-names>S</given-names></name><name><surname>Usal</surname><given-names>C</given-names></name><name><surname>Tesson</surname><given-names>L</given-names></name><name><surname>Anegon</surname><given-names>I</given-names></name><name><surname>Neveu</surname><given-names>I</given-names></name><name><surname>Damier</surname><given-names>P</given-names></name><name><surname>Naveilhan</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effects of Human α-Synuclein A53T-A30P Mutations on SVZ and Local Olfactory Bulb Cell Proliferation in a Transgenic Rat Model of Parkinson Disease</article-title><source>Parkinson’s Disease</source><year>2011</year><volume>2011</volume><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="R28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Anheim</surname><given-names>M</given-names></name><name><surname>Letournel</surname><given-names>F</given-names></name><name><surname>Bousset</surname><given-names>L</given-names></name><name><surname>Honoré</surname><given-names>A</given-names></name><name><surname>Rozas</surname><given-names>N</given-names></name><name><surname>Pieri</surname><given-names>L</given-names></name><name><surname>Madiona</surname><given-names>K</given-names></name><name><surname>Dürr</surname><given-names>A</given-names></name><name><surname>Melki</surname><given-names>R</given-names></name><etal/></person-group><article-title>G51D α-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome</article-title><source>Ann Neurol</source><year>2013</year><volume>73</volume><fpage>459</fpage><lpage>471</lpage></element-citation></ref><ref id="R29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>J</given-names></name></person-group><article-title>Graphical analysis of PET data applied to reversible and irreversible tracers</article-title><source>Nucl Med Biol</source><year>2000</year><volume>27</volume><fpage>661</fpage><lpage>670</lpage></element-citation></ref><ref id="R30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mali</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Esvelt</surname><given-names>KM</given-names></name><name><surname>Aach</surname><given-names>J</given-names></name><name><surname>Guell</surname><given-names>M</given-names></name><name><surname>DiCarlo</surname><given-names>JE</given-names></name><name><surname>Norville</surname><given-names>JE</given-names></name><name><surname>Church</surname><given-names>GM</given-names></name></person-group><article-title>RNA-guided human genome engineering via Cas9</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>823</fpage><lpage>826</lpage></element-citation></ref><ref id="R31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>R</given-names></name><name><surname>Baumgart</surname><given-names>D</given-names></name><name><surname>Hübner</surname><given-names>S</given-names></name><name><surname>Jüttler</surname><given-names>S</given-names></name><name><surname>Saul</surname><given-names>S</given-names></name><name><surname>Clausnitzer</surname><given-names>A</given-names></name><name><surname>Mollitor</surname><given-names>J</given-names></name><name><surname>Smits</surname><given-names>R</given-names></name><name><surname>Höpping</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name></person-group><article-title>Automated nucleophilic one-pot synthesis of <sup>18</sup>F-L- DOPA with high specific activity using the GE TRACERlab MX<sub>FDG</sub></article-title><source>J Label Compd Radiopharm</source><year>2013</year><volume>56</volume><fpage>S126</fpage></element-citation></ref><ref id="R32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrish</surname><given-names>PK</given-names></name><name><surname>Rakshi</surname><given-names>JS</given-names></name><name><surname>Bailey</surname><given-names>DL</given-names></name><name><surname>Sawle</surname><given-names>GV</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name></person-group><article-title>Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET</article-title><source>J Neurol Neurosurg Psychiatr</source><year>1998</year><volume>64</volume><fpage>314</fpage><lpage>319</lpage></element-citation></ref><ref id="R33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrish</surname><given-names>PK</given-names></name><name><surname>Sawle</surname><given-names>GV</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name></person-group><article-title>Clinical and [18F] dopa PET findings in early Parkinson’s disease</article-title><source>J Neurol Neurosurg Psychiatr</source><year>1995</year><volume>59</volume><fpage>597</fpage><lpage>600</lpage></element-citation></ref><ref id="R34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nahmias</surname><given-names>C</given-names></name><name><surname>Garnett</surname><given-names>ES</given-names></name><name><surname>Firnau</surname><given-names>G</given-names></name><name><surname>Lang</surname><given-names>A</given-names></name></person-group><article-title>Striatal dopamine distribution in parkinsonian patients during life</article-title><source>J Neurol Sci</source><year>1985</year><volume>69</volume><fpage>223</fpage><lpage>230</lpage></element-citation></ref><ref id="R35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuber</surname><given-names>S</given-names></name><name><surname>Harmuth</surname><given-names>F</given-names></name><name><surname>Kohl</surname><given-names>Z</given-names></name><name><surname>Adame</surname><given-names>A</given-names></name><name><surname>Trejo</surname><given-names>M</given-names></name><name><surname>Schönig</surname><given-names>K</given-names></name><name><surname>Zimmermann</surname><given-names>F</given-names></name><name><surname>Bauer</surname><given-names>C</given-names></name><name><surname>Casadei</surname><given-names>N</given-names></name><name><surname>Giel</surname><given-names>C</given-names></name><etal/></person-group><article-title>A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats</article-title><source>Brain</source><year>2013</year><volume>136</volume><fpage>412</fpage><lpage>432</lpage></element-citation></ref><ref id="R36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurmi</surname><given-names>E</given-names></name><name><surname>Ruottinen</surname><given-names>HM</given-names></name><name><surname>Bergman</surname><given-names>J</given-names></name><name><surname>Haaparanta</surname><given-names>M</given-names></name><name><surname>Solin</surname><given-names>O</given-names></name><name><surname>Sonninen</surname><given-names>P</given-names></name><name><surname>Rinne</surname><given-names>JO</given-names></name></person-group><article-title>Rate of progression in Parkinson’s disease: a 6-[18F]fluoro-L-dopa PET study</article-title><source>Mov Disord</source><year>2001</year><volume>16</volume><fpage>608</fpage><lpage>615</lpage></element-citation></ref><ref id="R37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrucci</surname><given-names>S</given-names></name><name><surname>Ginevrino</surname><given-names>M</given-names></name><name><surname>Valente</surname><given-names>EM</given-names></name></person-group><article-title>Phenotypic spectrum of α-synuclein mutations: New ls</article-title><source>Parkinsonism Relat Disord</source><year>2016</year><volume>22</volume><issue>1</issue><fpage>S16</fpage><lpage>S20</lpage></element-citation></ref><ref id="R38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reeve</surname><given-names>A</given-names></name><name><surname>Simcox</surname><given-names>E</given-names></name><name><surname>Turnbull</surname><given-names>D</given-names></name></person-group><article-title>Ageing and Parkinson’s disease: why is advancing age the biggest risk factor?</article-title><source>Ageing Res Rev</source><year>2014</year><volume>14</volume><fpage>19</fpage><lpage>30</lpage></element-citation></ref><ref id="R39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinne</surname><given-names>JO</given-names></name><name><surname>Portin</surname><given-names>R</given-names></name><name><surname>Ruottinen</surname><given-names>H</given-names></name><name><surname>Nurmi</surname><given-names>E</given-names></name><name><surname>Bergman</surname><given-names>J</given-names></name><name><surname>Haaparanta</surname><given-names>M</given-names></name><name><surname>Solin</surname><given-names>O</given-names></name></person-group><article-title>Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study</article-title><source>Arch Neurol</source><year>2000</year><volume>57</volume><fpage>470</fpage><lpage>475</lpage></element-citation></ref><ref id="R40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snow</surname><given-names>BJ</given-names></name><name><surname>Tooyama</surname><given-names>I</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Calne</surname><given-names>DB</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name></person-group><article-title>Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels</article-title><source>Ann Neurol</source><year>1993</year><volume>34</volume><fpage>324</fpage><lpage>330</lpage></element-citation></ref><ref id="R41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sossi</surname><given-names>V</given-names></name><name><surname>Doudet</surname><given-names>DJ</given-names></name><name><surname>Holden</surname><given-names>JE</given-names></name></person-group><article-title>A reversible tracer analysis approach to the study of effective dopamine turnover</article-title><source>J Cereb Blood Flow Metab</source><year>2001</year><volume>21</volume><fpage>469</fpage><lpage>476</lpage></element-citation></ref><ref id="R42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sossi</surname><given-names>V</given-names></name><name><surname>Dinelle</surname><given-names>K</given-names></name><name><surname>Topping</surname><given-names>GJ</given-names></name><name><surname>Holden</surname><given-names>JE</given-names></name><name><surname>Doudet</surname><given-names>D</given-names></name><name><surname>Schulzer</surname><given-names>M</given-names></name><name><surname>Ruth</surname><given-names>TJ</given-names></name><name><surname>Stoessl</surname><given-names>AJ</given-names></name><name><surname>de la Fuente-Fernández</surname><given-names>R</given-names></name></person-group><article-title>Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson’s: an in vivo imaging study</article-title><source>J Neurochem</source><year>2009</year><volume>109</volume><fpage>85</fpage><lpage>92</lpage></element-citation></ref><ref id="R43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sossi</surname><given-names>V</given-names></name><name><surname>de la Fuente-Fernández</surname><given-names>R</given-names></name><name><surname>Holden</surname><given-names>JE</given-names></name><name><surname>Doudet</surname><given-names>DJ</given-names></name><name><surname>McKenzie</surname><given-names>J</given-names></name><name><surname>Stoessl</surname><given-names>AJ</given-names></name><name><surname>Ruth</surname><given-names>TJ</given-names></name></person-group><article-title>Increase in dopamine turnover occurs early in Parkinson’s disease: evidence from a new modeling approach to PET 18 F-fluorodopa data</article-title><source>J Cereb Blood Flow Metab</source><year>2002</year><volume>22</volume><fpage>232</fpage><lpage>239</lpage></element-citation></ref><ref id="R44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sossi</surname><given-names>V</given-names></name><name><surname>de la Fuente-Fernández</surname><given-names>R</given-names></name><name><surname>Nandhagopal</surname><given-names>R</given-names></name><name><surname>Schulzer</surname><given-names>M</given-names></name><name><surname>McKenzie</surname><given-names>J</given-names></name><name><surname>Ruth</surname><given-names>TJ</given-names></name><name><surname>Aasly</surname><given-names>JO</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Wszolek</surname><given-names>ZK</given-names></name><name><surname>Stoessl</surname><given-names>JA</given-names></name></person-group><article-title>Dopamine turnover increases in asymptomatic LRRK2 mutations carriers</article-title><source>Mov Disord</source><year>2010</year><volume>25</volume><fpage>2717</fpage><lpage>2723</lpage></element-citation></ref><ref id="R45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Schmidt</surname><given-names>ML</given-names></name><name><surname>Lee</surname><given-names>VMY</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name></person-group><article-title>α-Synuclein in Lewy bodies</article-title><source>Nature</source><year>1997</year><volume>388</volume><fpage>839</fpage><lpage>840</lpage></element-citation></ref><ref id="R46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MD</given-names></name><name><surname>Dinelle</surname><given-names>K</given-names></name><name><surname>Kornelsen</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Stoessl</surname><given-names>AJ</given-names></name><name><surname>Sossi</surname><given-names>V</given-names></name></person-group><article-title>Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis</article-title><source>EJNMMI Res</source><year>2013a</year><volume>3</volume><fpage>69</fpage><lpage>11</lpage></element-citation></ref><ref id="R47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MD</given-names></name><name><surname>Dinelle</surname><given-names>K</given-names></name><name><surname>Kornelsen</surname><given-names>R</given-names></name><name><surname>McCormick</surname><given-names>S</given-names></name><name><surname>Mah</surname><given-names>C</given-names></name><name><surname>Holden</surname><given-names>JE</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Stoessl</surname><given-names>AJ</given-names></name><name><surname>Sossi</surname><given-names>V</given-names></name></person-group><article-title>In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET</article-title><source>J Cereb Blood Flow Metab</source><year>2013b</year><volume>33</volume><fpage>59</fpage><lpage>66</lpage></element-citation></ref><ref id="R48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshimi</surname><given-names>K</given-names></name><name><surname>Kaneko</surname><given-names>T</given-names></name><name><surname>Voigt</surname><given-names>B</given-names></name><name><surname>Mashimo</surname><given-names>T</given-names></name></person-group><article-title>Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR–Cas platform</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Genotyping of <italic>SNCA<sup>G51D</sup></italic> rats.</title><p>(A) Sanger sequencing of rat <italic>SNCA</italic> exon 3 of a WT and an <italic>SNCA</italic><sup>G51D/+</sup> F1 rat revealed a heterozygous mutation (G<bold>GA</bold>/G<bold>AT</bold>) at codon 51.(B) The G51D mutation generated a new <italic>Bsp</italic>HI restriction site (TCATGA) in exon 3. (C) <italic>SNCA</italic> exon 3 PCR and <italic>Bsp</italic>HI restriction enzyme digest can reliably genotype WT, <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats. (D) 44 neonatal (P2, P3) pups from five (5) <italic>SNCA</italic><sup>G51D/+</sup> X<italic>SNCA</italic><sup>G51D/+</sup> crosses were genotyped, and Mendelian ratios were observed.</p></caption><graphic xlink:href="EMS156677-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Representative PET-CT images and Standardized uptake value (SUV) time activity curves (TACs) for wild-type (WT) rats.</title><p>(A) PET-CT images of two WT rats are shown in coronal and transverse planes. <sup>18</sup>F-DOPA PET data averaged over frames 1-33 and smoothed using a 1mm x 1mm x 1mm Gaussian filter. HU-Hounsfield Units. Specific activity (B), SUV TAC data (C), and SUV ratio (SUVr) data (D) for the specific uptake of <sup>18</sup>F-DOPA into the striatum relative to the cerebellum is shown for two WT rats. The dashed box indicates the phase of pseudo-equilibrium (50 - 85 min).</p></caption><graphic xlink:href="EMS156677-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Patlak and Logan analysis for WT rats.</title><p>(A) Patlak graphical analysis of 60 min of data from the whole striatum of a WT rat relative to cerebellum. (B) Logan graphical analysis of 180 min of data from the whole striatum of a WT rat.</p></caption><graphic xlink:href="EMS156677-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Kinetic modelling of <sup>18</sup>F-DOPA PET data from WT, <italic>SNCA</italic><sup>G51D/+</sup> and <italic>SNCA</italic><sup>G51D/G51D</sup> rats at 5, 11 and 16 months of age.</title><p>(A) Standardized uptake value (SUV) time activity curves (TACs) for all rat genotypes – WT, <italic>SNCA</italic><sup>G51D/+</sup>, and <italic>SNCA</italic><sup>G51D/G51D</sup> rats, n=4 per genotype per age-group. m-months old, Str.- Striatum, Cer.-Cerebellum. (B) The mean <italic>K<sub>i</sub></italic> in the striatum of 5-16 month old WT, <italic>SNCA</italic><sup>G51D/+</sup>and <italic>SNCA</italic><sup>G51D/G51D</sup> rats. (C) There was a significant decrease in mean <italic>DVR</italic> of <sup>18</sup>F-DOPA in 16 month old <italic>SNCA</italic><sup>G51D/G51D</sup> rats when compared with age-matched WT rats (p=0.0348), and (D) also a significant decrease in <italic>EDVR</italic> of <sup>18</sup>F-DOPA in 16 months <italic>SNCA</italic><sup>G51D/G51D</sup>rats compared with age-matched WT rats (p=0.0215). (E) Mean left-right asymmetry in <italic>EDVR</italic> was greatest in16 month old <italic>SNCA</italic><sup>G51D/+</sup>and <italic>SNCA</italic><sup>G51D/G51D</sup>rats.Data shows the mean, SEM and individual data-points. n=4 per genotype per age-group. One-way ANOVA with Tukey’s multiple comparison test. L-left striatum, R-right striatum, m-months old.</p></caption><graphic xlink:href="EMS156677-f004"/></fig></floats-group></article>